Though many studies have reviewed the effect of Risperidone Long Acting Injections (RLAI) in regards to reducing symptoms associated with schizophrenia and schizoaffective disorder, prior studies have not looked into the effect of RLAI on recovery-oriented outcomes. The current study looks at how RLAI treatment affected the overall progression of recovery as measured by the Recovery Markers Inventory (RMI; Clinician perspective of consumer recovery). As part of the RMI, the influence of RLAI on jail days, detoxification facility days, physical health hospitalization days, and psychiatric hospitalization days were also reviewed.